Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | FNTA | P49354 | 3/20 | 0.55 |
| ▸ | FNTB | P49356 | 3/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7818410 | 0.99 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7939449 | 0.86 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL3824590 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL3932992 | 0.82 | CYP11B1 (0.56) | CYP11B1CYP11B2 | |
| SCHEMBL8182963 | 0.81 | CYP11B1 (0.61) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL15795442 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL7169286 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2786255 | 0.81 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7488391 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL28186334 | 0.80 | CYP11B1 (0.54) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | PIERRE FABRE MEDICAMENT (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1324999-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030927-A1 | NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME | PIERRE FABRE MEDICAMENT (FR) | 2002-04-18 | — | — | WO | disclosed |
| EP-0944388-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6248756-B1 | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092524-A1 | Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same | CBR3, CBR1, HCCS | CYP11B1 519/4885CYP11B2 790/4885CYP19A1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.